Glenmark Pharmaceuticals is currently trading at Rs. 524.10, up by 15.05 points or 2.96 % from its previous closing of Rs. 509.05 on the BSE.
The scrip opened at Rs. 513.50 and has touched a high and low of Rs. 527.70 and Rs. 510.30 respectively. So far 43481 shares were traded on the counter.
The BSE group 'A' stock of face value Re 1 has touched a 52 week high of Rs. 612.00 on 12-Jul-2013 and a 52 week low of Rs. 458.00 on 28-Mar-2013.
Last one week high and low of the scrip stood at Rs. 514.15 and Rs. 499.30 respectively. The current market cap of the company is Rs. 14199.42 crore.
The promoters holding in the company stood at 48.30% while Institutions and Non-Institutions held 40.64% and 11.06% respectively.
Glenmark Pharmaceuticals has reported 46.44% fall in its net profit at Rs 58.40 crore for third quarter ended December 31, 2013.as compared to Rs 109.03 crore for the same quarter in the previous year. Total income from operations of the company decreased by 2.30% at Rs 543.16 crore for quarter under review, as compared to Rs 555.94 crore for the quarter ended December 31, 2012.
On the consolidated basis, the group has reported modest 1.56% rise in its net profit at Rs 216.23 crore for the quarter as compared to Rs 212.91 crore for the same quarter in the previous year. Total income from operations of the company has increased by 15.87% at Rs 1606.83 crore for quarter under review as compared to Rs 1386.76 crore for the quarter ended December 31, 2012.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1787.50 |
Dr. Reddys Lab | 1354.90 |
Cipla | 1469.65 |
Lupin | 2192.50 |
Zydus Lifesciences | 1003.25 |
View more.. |